Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study
نویسندگان
چکیده
منابع مشابه
A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis
BACKGROUND While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. AIMS The current study assessed the effectiveness of itolizumab in real-world settings. MATERIALS AND METHODS This study assessed psoriasis area severity index (...
متن کاملSecukinumab in plaque psoriasis--results of two phase 3 trials.
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Inve...
متن کاملA 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
BACKGROUND Patients with moderate to severe plaque psoriasis demonstrated positive responses to ixekizumab, an anti-interleukin-17A monoclonal antibody, in a phase-II, randomized, placebo-controlled trial. OBJECTIVE We sought to evaluate long-term efficacy and safety of ixekizumab. METHODS After receiving 10, 25, 75, or 150 mg of ixekizumab or placebo during randomized, placebo-controlled t...
متن کاملPrevalence of Lymph Node Metastasis in Radical Prostatectomy; A Retrospective and Multicenter Study in Iran
Lymph node (LN) metastasis is considered an important prognostic factor in patients with prostate cancer. The aim of this study was to determine the rate of LN metastasis among an Iranian population who underwent radical prostatectomy (RP) with pelvic LN dissection (PLND). In a retrospective review of medical records, 450 RP cases were included and the data on LN metastasis were extracted from ...
متن کاملA 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
BACKGROUND Briakinumab is a monoclonal antibody against the p40 molecule shared by interleukin-12 and interleukin-23, which is overexpressed in psoriatic skin lesions. We assessed the efficacy and safety of briakinumab as compared with methotrexate in patients with psoriasis. METHODS In this 52-week trial, we randomly assigned 317 patients with moderate-to-severe psoriasis to briakinumab, at ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American Academy of Dermatology
سال: 2018
ISSN: 0190-9622
DOI: 10.1016/j.jaad.2017.11.036